benefits of microdosing glp-1 agonists ✨ Microdosing: A Thoughtful, Evidence-Based Approach ✨ GLP-1 medications are often reserved for patients who meet specific BMI or metabolic criteria—but emerging research suggests that very low-dose (“ microdosing”) GLP-1 therapy may What Is Microdosing GLP-1s, and

Emerging evidencestrengthened by ASCO GI 2026suggests that GLP-1 receptor agonists may define the next era by addressing the metabolic roots of colorectal carcinogenesis

Results from a 20-week phase 1b clinical trial showed that a once-weekly dose of 2.4 mg cagrilintide in combination with an equal dose of semaglutide, collectively termed cagrisema, achieved up to 17.1% weight reduction in the obese population

Oxidative stress is a major contributor to renal injury and is characterized by increased superoxide production, upregulation of NADPH oxidase, and impaired cAMPPKA signaling (Greco et al

We have added it to a list of your favorite stories

Ask your doctor about patient assistance programs

Compared with the other medications, people taking the GLP-1 drugs had a reduced risk for addiction: 18 per cent for alcohol, 14 per cent for cannabis, 20 per cent for both cocaine and nicotine, and 25 per cent for opioids